Gastroesophageal Reflux Disease
The objective of this study is to evaluate the safety and efficacy of XXX administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily, standard-dose proton pump inhibitors (PPIs) such a Nexium, Prilosec or Dexilant.
- Patient is an ambulatory male or female (if female, nonpregnant) and is at least 18 years old at the Screening Visit.
- Patient has a diagnosis of GERD and reports experiencing GERD symptoms (heartburn or regurgitation) while taking standard proton pump inhibitor (PPI) such as Nexium, Prilosec or Dexilant therapy.
- Female patients must not be pregnant and must agree to avoid pregnancy for the duration of the study.
- Patient must comply with study procedures.
The study is 8 weeks long.
The trial doctor will review other eligibility criteria with you. All trial-related visits, tests, and medications will be provided to you at no cost. In addition, reimbursement for trial-related time and travel may be provided.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03561090